RNA interference (RNAi) is a cellular mechanism that can be induced by small interfering RNAs (siRNAs) to mediate sequence-specific gene silencing by cleavage of the targeted messenger RNA. RNAi can be used as an antiviral approach to silence HIV type-1 (HIV-1) through stable expression of precursors, such as short hairpin RNAs (shRNAs), which are processed into siRNAs that can elicit degradation of HIV-1 RNAs. At the beginning of 2008, the first clinical trial using a lentivirus with an RNA-based gene therapy against HIV-1 was initiated. The antiviral molecules in this gene therapy consist of three RNA effectors, one of which triggers the RNAi pathway. This review article focuses on the basic principles of an RNAi-based gene therapy against HIV-1, including delivery methods, target selection, viral escape possibilities, systems for multiplexing siRNAs to achieve a durable therapy and the in vitro and in vivo test systems to evaluate the efficacy and safety of such a therapy.
References
1.
Barre-SinoussiFChermannJCReyP. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science1983; 220: 868–871.
2.
GalloRCSalahuddinSZPopovicM. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science1984; 224: 500–503.
3.
CastanottoDRossiJJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature2009; 457: 426–433.
4.
DingHSchwarzDSKeeneA. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell2003; 2: 209–217.
5.
McCaffreyAPNakaiHPandeyK. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol2003; 21: 639–644.
6.
TakeshitaFOchiyaT. Therapeutic potential of RNA interference against cancer. Cancer Sci2006; 97: 689–696.
7.
DavidsonBLPaulsonHL. Molecular medicine for the brain: Silencing of disease genes with RNA interference. Lancet Neurol2004; 3: 145–149.
8.
KapadiaSBBrideau-AndersenAChisariFV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci U S A2003; 100: 2014–2018.
9.
BanerjeaALiMJBauerG. Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. Mol Ther2003; 8: 62–71.
10.
ter BrakeOLegrandNvon EijeKJ. Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)(c)(-/-)) mouse model. Gene Ther2009; 16: 148–153.
11.
MelloCC. Return to the RNAi world: Rethinking gene expression and evolution (Nobel Lecture). Angew Chem Int Ed Engl2007; 46: 6985–6994.
12.
AmbrosV. microRNAs: Tiny regulators with great potential. Cell2001; 107: 823–826.
DenliAMTopsBBPlasterkRHKettingRFHannonGJ. Processing of primary microRNAs by the microprocessor complex. Nature2004; 432: 231–235.
22.
GregoryRIYanKPAmuthanG. The microprocessor complex mediates the genesis of microRNAs. Nature2004; 432: 235–240.
23.
HanJLeeYYeomKHKimYKJinHKimVN. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev2004; 18: 3016–3027.
24.
LandthalerMYalcinATuschlT. The human DiGeorge syndrome critical region gene 8 and its D. melanogaster homolog are required for miRNA biogenesis. Curr Biol2004; 14: 2162–2167.
25.
LeeYAhnCHanJ. The nuclear RNase III Drosha initiates microRNA processing. Nature2003; 425: 415–419.
ChanSPSlackFJ. And now introducing mammalian mirtrons. Dev Cell2007; 13: 605–607.
28.
BohnsackMTCzaplinskiKGorlichD. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA2004; 10: 185–191.
29.
LundEGuttingerSCaladoADahlbergJEKutayU. Nuclear export of microRNA precursors. Science2004; 303: 95–98.
30.
YiRQinYMacAraIGCullenBR. Exportin–5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev2003; 17: 3011–3016.
31.
ZhangHKolbFAJaskiewiczLWesthofEFilipowiczW. Single processing center models for human Dicer and bacterial RNase III. Cell2004; 118: 57–68.
32.
ChendrimadaTPGregoryRIKumaraswamyE. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature2005; 436: 740–744.
33.
GregoryRIChendrimadaTPCoochNShiekhattarR. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell2005; 123: 631–640.
34.
ManiatakiEMourelatosZ. A human, ATP-independent, RISC assembly machine fueled by pre-miRNA. Genes Dev2005; 19: 2979–2990.
35.
HammondSMBoettcherSCaudyAAKobayashiRHannonGJ. Argonaute2, a link between genetic and biochemical analyses of RNAi. Science2001; 293: 1146–1150.
36.
TomariYZamorePD. Perspective: Machines for RNAi. Genes Dev2005; 19: 517–529.
37.
TomariYMatrangaCHaleyBMartinezNZamorePD. A protein sensor for siRNA asymmetry. Science2004; 306: 1377–1380.
38.
BrenneckeJHipfnerDRStarkARussellRBCohenSM. Bantam Encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell2003; 113: 25–36.
39.
DoenchJGSharpPA. Specificity of microRNA target selection in translational repression. Genes Dev2004; 18: 504–511.
40.
KiriakidouMNelsonPTKouranovA. A combined computational-experimental approach predicts human microRNA targets. Genes Dev2004; 18: 1165–1178.
41.
LaiEC. Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet2002; 30: 363–364.
42.
LewisBPShihIHJones-RhoadesMWBartelDPBurgeCB. Prediction of mammalian microRNA targets. Cell2003; 115: 787–798.
43.
SaetromPHealeBSSnoveOJr.AagaardLAlluinJRossiJJ. Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res2007; 35: 2333–2342.
44.
YektaSShihIHBartelDP. microRNA-directed cleavage of HOXB8 mRNA. Science2004; 304: 594–596.
45.
ElbashirSMHarborthJLendeckelWYalcinAWeberKTuschlT. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature2001; 411: 494–498.
46.
BrummelkampTRBernardsRAgamiR. A system for stable expression of short interfering RNAs in mammalian cells. Science2002; 296: 550–553.
47.
PaddisonPJCaudyAABernsteinEHannonGJConklinDS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev2002; 16: 948–958.
48.
ZengYWagnerEJCullenBR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell2002; 9: 1327–1333.
49.
GrimmDStreetzKLJoplingCL. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature2006; 441: 537–541.
50.
McBrideJLBoudreauRLHarperSQ. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A2008; 105: 5868–5873.
51.
BoudreauRLMonteysAMDavidsonBL. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA2008; 14: 1834–1844.
52.
CastanottoDSakuraiKLingemanR. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res2007; 35: 5154–5164.
53.
VickersTALimaWFNicholsJGCrookeST. Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells. Nucleic Acids Res2007; 35: 6598–6610.
54.
BrenneckeJStarkARussellRBCohenSM. Principles of microRNA-target recognition. PLoS Biol2005; 3: e85.
FedorovYAndersonEMBirminghamA. Off-target effects by siRNA can induce toxic phenotype. RNA2006; 12: 1188–1196.
57.
JacksonALBurchardJSchelterJ. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA2006; 12: 1179–1187.
58.
BirminghamAAndersonEMReynoldsA. 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods2006; 3: 199–204.
59.
BridgeAJPebernardSDucrauxANicoulazALIggoR. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet2003; 34: 263–264.
60.
SledzCAHolkoMde VeerMJSilvermanRHWilliamsBR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol2003; 5: 834–839.
61.
MarquesJTWilliamsBR. Activation of the mammalian immune system by siRNAs. Nat Biotechnol2005; 23: 1399–1405.
62.
KumarPBanHSKimSS. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell2008; 134: 577–586.
63.
NaldiniLBlomerUGallayP. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science1996; 272: 263–267.
64.
WeicholdFFZellaDBarabitskajaO. Neither human immunodeficiency virus-1 (HIV-1) nor HIV-2 infects most-primitive human hematopoietic stem cells as assessed in long-term bone marrow cultures. Blood1998; 91: 907–915.
AmadoRGMitsuyasuRTRosenblattJD. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther2004; 15: 251–262.
67.
MichienziACastanottoDLeeNLiSZaiaJARossiJJ. RNA-mediated inhibition of HIV in a gene therapy setting. Ann N Y Acad Sci2003; 1002: 63–71.
68.
MitsuyasuRTMeriganTCCarrA. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med2009; 15: 285–292.
69.
DropulicB. Lentivirus in the clinic. Mol Ther2001; 4: 511–512.
70.
BodenDPuschOLeeFTuckerLRamratnamB. Human immunodeficiency virus type 1 escape from RNA interference. J Virol2003; 77: 11531–11535.
71.
DasATBrummelkampTRWesterhoutEM. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol2004; 78: 2601–2605.
72.
NishitsujiHKoharaMKannagiMMasudaT. Effective suppression of human immunodeficiency virus type 1 through a combination of short- or long-hairpin RNAs targeting essential sequences for retroviral integration. J Virol2006; 80: 7658–7666.
73.
SabariegosRGimenez-BarconsMTapiaNClotetBMartinezMA. Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J Virol2006; 80: 571–577.
74.
ter BrakeOKonstantinovaPCeylanMBerkhoutB. Silencing of HIV-1 with RNA interference: A multiple shRNA approach. Mol Ther2006; 14: 883–892.
75.
UnwallaHJLiHTBahnerILiMJKohnDRossiJJ. Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein. J Virol2006; 80: 1863–1873.
76.
WesterhoutEMOomsMVinkMDasATBerkhoutB. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res2005; 33: 796–804.
77.
HaasnootJWesterhoutEMBerkhoutB. RNA interference against viruses: Strike and counterstrike. Nat Biotechnol2007; 25: 1435–1443.
78.
von EijeKJter BrakeOBerkhoutB. Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J Virol2008; 82: 2895–2903.
79.
ter BrakeO't HooftKLiuYPCentlivreMvon EijeKJBerkhoutB. Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther2008; 16: 557–564.
80.
LiMJKimJLiS. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther2005; 12: 900–909.
81.
ter BrakeOBerkhoutB. A novel approach for inhibition of HIV-1 by RNA interference: Counteracting viral escape with a second generation of siRNAs. Journal of RNAi and Gene Silencing2005; 1: 56–65.
82.
ter BrakeOBerkhoutB. Lentiviral vectors that carry anti-HIV shRNAs: Problems and solutions. J Gene Med2007; 9: 743–750.
83.
SalmonPTronoD. Production and titration of lentiviral vectors. Curr Protoc Neurosci2006; Chapter 4: Unit 4.21.
84.
NguyenTMenocalEMHarborthJFruehaufJH. RNAi therapeutics: An update on delivery. Curr Opin Mol Ther2008; 10: 158–167.
85.
de FougerollesAR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther2008; 19: 125–132.
86.
WesterhoutEMBerkhoutB. A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res2007; 35: 4322–4330.
87.
JacqueJMTriquesKStevensonM. Modulation of HIV-1 replication by RNA interference. Nature2002; 418: 435–438.
88.
ChangLJLiuXHeJ. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1. Gene Ther2005; 12: 1133–1144.
89.
BerkhoutBter BrakeO. Towards an RNAi-based gene therapy. BIOforum Europe2008; 4: 35–37.
90.
NovinaCDMurrayMFDykxhoornDM. siRNA-directed inhibition of HIV-1 infection. Nat Med2002; 8: 681–686.
91.
ParkWSMiyano-KurosakiNHayafuneM. Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference. Nucleic Acids Res2002; 30: 4830–4835.
92.
SurabhiRMGaynorRB. RNA interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication. J Virol2002; 76: 12963–12973.
93.
CoburnGACullenBR. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol2002; 76: 9225–9231.
94.
LeeNSDohjimaTBauerG. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol2002; 20: 500–505.
95.
von EijeKJter BrakeOBerkhoutB. Stringent testing identifies highly potent and escape-proof anti-HIV short hairpin RNAs. J Gene Med2009; 11: 459–467.
96.
MartinezMAGutierrezAArmand-UgonM. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS2002; 16: 2385–2390.
97.
IshaqMHuJWuX. Knockdown of cellular RNA helicase DDX3 by short hairpin RNAs suppresses HIV-1 viral replication without inducing apoptosis. Mol Biotechnol2008; 39: 231–238.
98.
VandekerckhoveLChristFVan MaeleB. Transient and stable knockdown of the integrase cofactor LEDGF/ p75 reveals its role in the replication cycle of human immunodeficiency virus. J Virol2006; 80: 1886–1896.
99.
AnDSDonahueREKamataM. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci U S A2007; 104: 13110–13115.
100.
LimJKGlassWGMcDermottDHMurphyPM. CCR5: No longer a “good for nothing” gene — Chemokine control of West Nile virus infection. Trends Immunol2006; 27: 308–312.
101.
AndersonJBanerjeaAAkkinaR. Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides2003; 13: 303–312.
102.
AnDSQinFXAuyeungVC. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther2006; 14: 494–504.
103.
LapidotT. Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. The role of SDF-1/CXCR4 interactions. Ann N Y Acad Sci2001; 938: 83–95.
104.
BrassALDykxhoornDMBenitaY. Identification of host proteins required for HIV infection through a functional genomic screen. Science2008; 319: 921–926.
105.
ZhouHXuMHuangQ. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe2008; 4: 495–504.
106.
KonigRZhouYEllederD. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell2008; 135: 49–60.
107.
LisziewiczJSunDSmytheJ. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci U S A1993; 90: 8000–8004.
108.
SarverNCantinEMChangPS. Ribozymes as potential anti-HIV-1 therapeutic agents. Science1990; 247: 1222–1225.
109.
LiuYPBerkhoutB. Combinatorial RNAi strategies against HIV-1 and other escape-prone viruses. International Journal of BioSciences and Technology2008; 1: 1–10.
110.
GrimmDKayMA. Combinatorial RNAi: A winning strategy for the race against evolving targets?Mol Ther2007; 15: 878–888.
111.
ChatterjeeSJohnsonPRWongKKJr.Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science1992; 258: 1485–1488.
112.
LevineBLHumeauLMBoyerJ. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A2006; 103: 17372–17377.
113.
KohnDBBauerGRiceCR. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood1999; 94: 368–371.
114.
SymensmaTLGiverLZappMTakleGBEllingtonAD. RNA aptamers selected to bind human immunodeficiency virus type 1 Rev in vitro are Rev responsive in vivo. J Virol1996; 70: 179–187.
115.
WeinbergMSVilleneuveLMEhsaniA. The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA2006; 12: 256–262.
116.
AbadXVeraMJungSP. Requirements for gene silencing mediated by U1 snRNA binding to a target sequence. Nucleic Acids Res2008; 36: 2338–2352.
117.
LiuYPHaasnootJBerkhoutB. Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res2007; 35: 5683–5693.
118.
BarichievySSaaymanSvon EijeKJMorrisKVArbuthnotPWeinbergMS. The inhibitory efficacy of RNA POL III-expressed long hairpin RNAs targeted to untranslated regions of the HIV-1 5′ long terminal repeat. Oligonucleotides2007; 17: 419–431.
119.
SanoMLiHNakanishiMRossiJJ. Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: Advantages and limitations. Mol Ther2008; 16: 170–177.
120.
KonstantinovaPde VriesWHaasnootJter BrakeOde HaanPBerkhoutB. Inhibition of human immunodeficiency virus type 1 by RNA interference using long-hairpin RNA. Gene Ther2006; 13: 1403–1413.
121.
AagaardLAZhangJvon EijeKJ. Engineering and optimization of the miR–106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther2008; 15: 1536–1549.
122.
LiuYPHaasnootJter BrakeOBerkhoutBKonstantinovaP. Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res2008; 36: 2811–2824.
123.
SnyderLLEsserJMPachukCJSteelLF. Vector design for liver-specific expression of multiple interfering RNAs that target hepatitis B virus transcripts. Antiviral Res2008; 80: 36–44.
ZhouXSymonsJHoppesR. Improved single-chain transactivators of the Tet-On gene expression system. BMC Biotechnol2007; 7: 6.
126.
LacknerAAVeazeyRS. Current concepts in AIDS pathogenesis: Insights from the SIV/macaque model. Annu Rev Med2007; 58: 461–476.
127.
StremlauMOwensCMPerronMJKiesslingMAutissierPSodroskiJ. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature2004; 427: 848–853.
128.
HatziioannouTAmbroseZChungNPY. A macaque model of HIV-1 infection. Proc Natl Acad Sci U S A2009; 106: 4425–4429.
129.
TraggiaiEChichaLMazzucchelliL. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science2004; 304: 104–107.
130.
GimenoRWeijerKVoordouwA. Monitoring the effect of gene silencing by RNA interference in human CD34+ cells injected into newborn RAG2-/-γc-/- mice: Functional inactivation of p53 in developing T cells. Blood2004; 104: 3886–3893.
131.
LegrandNWeijerKSpitsH. Experimental models to study development and function of the human immune system in vivo. J Immunol2006; 176: 2053–2058.
ManzMG. Human-hemato-lymphoid-system mice: Opportunities and challenges. Immunity2007; 26: 537–541.
134.
LegrandNCupedoTvan LentAU. Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in “human immune system” Rag2(-/-)γc(-/-) mice. Blood2006; 108: 238–245.
135.
BaenzigerSTussiwandRSchlaepferE. Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-γc-/- mice. Proc Natl Acad Sci U S A2006; 103: 15951–15956.
136.
ZhangLKovalevGISuL. HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood2007; 109: 2978–2981.
137.
WatanabeSTerashimaKOhtaS. Hematopoietic stem cell-engrafted NOD/SCID/IL2Rγnull mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood2007; 109: 212–218.
138.
BergesBKWheatWHPalmerBEConnickEAkkinaR. HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-γ c-/- (RAG-hu) mouse model. Retrovirology2006; 3: 76.
139.
AnDSPoonBTsongHo FR. Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection. Clin Vaccine Immunol2007; 14: 391–396.
140.
BergesBKAkkinaSRFolkvordJMConnickEAkkinaR. Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2(-/-)γc(-/-) (RAG-hu) mice. Virology2008; 373: 342–351.
141.
GoldsteinH. Summary of presentations at the NIH/NIAID New Humanized Rodent Models 2007 Workshop. AIDS Res Ther2008; 5: 3.
MarshallE. Gene therapy death prompts review of adenovirus vector. Science1999; 286: 2244–2245.
144.
Hacein-Bey-AbinaSLe DeistFCarlierF. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med2002; 346: 1185–1193.
145.
Hacein-Bey-AbinaSVon KalleCSchmidtM. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science2003; 302: 415–419.
146.
EdelsteinMLAbediMRWixonJ. Gene therapy clinical trials worldwide to 2007 — An update. J Gene Med2007; 9: 833–842.
147.
RossiJJJuneCHKohnDB. Genetic therapies against HIV. Nat Biotechnol2007; 25: 1444–1454.
148.
Cartier-LacaveN. Hematopoietic stem cell gene therapy trial with lentiviral vector in X-linked adrenoleukodystrophy. Hum Gene Ther2008; 19: 1061
149.
MontiniECesanaDSchmidtM. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol2006; 24: 687–696.
150.
BushmanFLewinskiMCiuffiA. Genome-wide analysis of retroviral DNA integration. Nat Rev Microbiol2005; 3: 848–858.
151.
ManillaPRebelloTAfableC. Regulatory considerations for novel gene therapy products: A review of the process leading to the first clinical lentiviral vector. Hum Gene Ther2005; 16: 17–25.
152.
RobbinsMJudgeAAmbegiaE. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther2008; 19: 991–999.
153.
KleinmanMEYamadaKTakedaA. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature2008; 452: 591–597.
